Biosimilars

Extrapolation for oncology

Giuseppe Curigliano, Darran P. O'Connor, Julie A. Rosenberg, Ira Jacobs

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A biosimilar is a biologic that is highly similar to a licensed biologic (the reference product) in terms of purity, safety and efficacy. If the reference product is licensed to treat multiple therapeutic indications, extrapolation of indications, i.e., approval of a biosimilar for use in an indication held by the reference product but not directly studied in a comparative clinical trial with the biosimilar, may be possible but has to be scientifically justified. Here, we describe the data required to establish biosimilarity and emphasize that indication extrapolation is based on scientific principles and known mechanism of action.

Original languageEnglish
JournalCritical Reviews in Oncology/Hematology
DOIs
Publication statusAccepted/In press - Jan 22 2016

Fingerprint

Biosimilar Pharmaceuticals
Biological Products
Clinical Trials
Safety

Keywords

  • Biosimilar
  • Cancer
  • Extrapolation
  • Monoclonal antibody

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Biosimilars : Extrapolation for oncology. / Curigliano, Giuseppe; O'Connor, Darran P.; Rosenberg, Julie A.; Jacobs, Ira.

In: Critical Reviews in Oncology/Hematology, 22.01.2016.

Research output: Contribution to journalArticle

Curigliano, Giuseppe ; O'Connor, Darran P. ; Rosenberg, Julie A. ; Jacobs, Ira. / Biosimilars : Extrapolation for oncology. In: Critical Reviews in Oncology/Hematology. 2016.
@article{b2c3e7e65519443bb8a2eca78cdf60d7,
title = "Biosimilars: Extrapolation for oncology",
abstract = "A biosimilar is a biologic that is highly similar to a licensed biologic (the reference product) in terms of purity, safety and efficacy. If the reference product is licensed to treat multiple therapeutic indications, extrapolation of indications, i.e., approval of a biosimilar for use in an indication held by the reference product but not directly studied in a comparative clinical trial with the biosimilar, may be possible but has to be scientifically justified. Here, we describe the data required to establish biosimilarity and emphasize that indication extrapolation is based on scientific principles and known mechanism of action.",
keywords = "Biosimilar, Cancer, Extrapolation, Monoclonal antibody",
author = "Giuseppe Curigliano and O'Connor, {Darran P.} and Rosenberg, {Julie A.} and Ira Jacobs",
year = "2016",
month = "1",
day = "22",
doi = "10.1016/j.critrevonc.2016.06.002",
language = "English",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Biosimilars

T2 - Extrapolation for oncology

AU - Curigliano, Giuseppe

AU - O'Connor, Darran P.

AU - Rosenberg, Julie A.

AU - Jacobs, Ira

PY - 2016/1/22

Y1 - 2016/1/22

N2 - A biosimilar is a biologic that is highly similar to a licensed biologic (the reference product) in terms of purity, safety and efficacy. If the reference product is licensed to treat multiple therapeutic indications, extrapolation of indications, i.e., approval of a biosimilar for use in an indication held by the reference product but not directly studied in a comparative clinical trial with the biosimilar, may be possible but has to be scientifically justified. Here, we describe the data required to establish biosimilarity and emphasize that indication extrapolation is based on scientific principles and known mechanism of action.

AB - A biosimilar is a biologic that is highly similar to a licensed biologic (the reference product) in terms of purity, safety and efficacy. If the reference product is licensed to treat multiple therapeutic indications, extrapolation of indications, i.e., approval of a biosimilar for use in an indication held by the reference product but not directly studied in a comparative clinical trial with the biosimilar, may be possible but has to be scientifically justified. Here, we describe the data required to establish biosimilarity and emphasize that indication extrapolation is based on scientific principles and known mechanism of action.

KW - Biosimilar

KW - Cancer

KW - Extrapolation

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=84977500678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977500678&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.06.002

DO - 10.1016/j.critrevonc.2016.06.002

M3 - Article

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -